Document is current

Article History

Received: 3 June 2024

Accepted: 16 August 2024

First Online: 8 October 2024

Declarations

:

: The Ludwig Maximilian University of Munich institutional review board approved this analysis (reference numbers 17–230 and 17–233).

: Informed consent was obtained from all individual participants included in the study.

: The authors affirm that human research participants provided informed consent for publication.

: The Department of Radiation Oncology of the LMU University Hospital, LMU Munich has research agreements with ViewRay Inc., Elekta, Brainlab, and C-RAD outside the submitted work. ABZ, SK, JG, SH, SM, NR, LK, NSSH, AT, and JD report no conflicts of interest. AH reports compensation for scientific consulting by ABX advanced biochemical compounds, unrelated to the current study. FM reports a research grant from AstraZeneca and honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab outside the submitted work. FM serves on the advisory board of AstraZeneca, Novartis. CB reports receiving grants or contracts from ViewRay, Brainlab, and Elekta; payment or honoraria from Bristol-Myers Squibb, Roche, Merck, AstraZeneca, Opasca, C-RAD, Elekta, and ViewRay; receiving support for attending meetings or travel from Bristol-Myers Squibb, Roche, Merck, AstraZeneca, Elekta, and ViewRay; and having a leadership or fiduciary role with ESTRO, all outside the submitted work. CE reports consulting fees from Novartis outside the submitted work.